Abstracts tagged "Biologic agents"

Abstract Number: 1536 • 2016 ACR/ARHP Annual Meeting
Sleep Disturbance in Patients with Rheumatoid Arthritis – a Cross-Section Study
Lingshu Zhang¹, Yuan Xu², Yi Liu³ and Cong-Qiu Chu⁴, ¹Department of Rheumatology, West China Hospital, Sichuan University, Chengdu, China, ²The First Affiliated Hospital of Southwest Medical University, Suzhou, China, ³Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, China, ⁴Rheumatology, Oregon Health & Science University, Portland, OR
Background/Purpose: Sleep disturbance is common in patients with rheumatoid arthritis (RA). Poor sleep can result in increased psychological distress, depression, fatigue, inability to work, socioeconomic…
Abstract Number: 2233 • 2016 ACR/ARHP Annual Meeting
Predictors of Adherence and Costs in First and Second Years after Biologic Initiation in Patients with Rheumatoid Arthritis (RA)
Bradley S. Stolshek¹, Sally W. Wade², Ajita De³, Ron L. Wade³ and Jason Yeaw³, ¹Amgen, Thousand Oaks, CA, ²Wade Outcomes Research and Consulting, Salt Lake City, UT, ³IMS Health, Plymouth Meeting, PA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease requiring continuous therapy to reach low disease activity targets and to delay its long-term health effects.…
Abstract Number: 2646 • 2016 ACR/ARHP Annual Meeting
Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): A Systematic Review and Meta-Analysis
Tzu-Chieh Lin¹, Mirhelen Mendes De Abreu², Sara K. Tedeschi¹, Kazuki Yoshida³ and Daniel H. Solomon², ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Department of Epidemiology, Harvard School of Public Health, Boston, MA
Background/Purpose: There is limited information for the rate of hepatitis B reactivation in inflammatory arthritis patients. We conducted a systematic review and meta-analysis, assessing hepatitis…
Abstract Number: 3244 • 2016 ACR/ARHP Annual Meeting
Observations of Early and Late B Cell Alterations during Belimumab Treatment in Patients with Systemic Lupus Erythematosus Using Mass Cytometry (CyTOF)
Ioannis Parodis¹, Daniel Ramsköld¹, Petter Brodin², Agneta Zickert¹, Lakshmikanth Tadepally², Yang Chen², Jaromir Mikes², Adnane Achour², Iva Gunnarsson¹ and Vivianne Malmström¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Science for Life Laboratory, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Belimumab is a recombinant monoclonal antibody that inhibits soluble B lymphocyte stimulator (BLyS), also known as BAFF or TNFSF13B, and is approved for treating…
Abstract Number: 3L • 2015 ACR/ARHP Annual Meeting
A Randomised Controlled Trial of the Clinical Effectiveness, Safety and Cost-Effectiveness of Adalimumab in Combination with Methotrexate for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis
Athimalaipet V Ramanan¹, Andrew D. Dick², Andrew McKay³, Ashley Jones⁴, Paula Williamson⁴, Sandrine Compeyrot-Lacassagne⁵, Ben Hardwick⁴, Helen Hickey⁴, Dyfrig Hughes⁶, Patricia Woo⁵, Diana Benton¹, Clive Edelsten⁵ and Michael W. Beresford⁷, ¹University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom, ²University of Bristol, Bristol Eye Hospital, Bristol, United Kingdom, ³Biostatistics, Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁴Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁵Great Ormond Street Hospital, London, United Kingdom, ⁶Bangor University, Bangor, United Kingdom, ⁷University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Uveitis associated with Juvenile Idiopathic Arthritis (JIA) is a major cause of morbidity with potentially sight-threatening complications. Despite current screening and (pre-biologic) therapeutic options,…
Abstract Number: 4L • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
Megan E. B. Clowse¹, Daniel J Wallace², Richard Furie³, Michelle Petri⁴, Marilyn Pike⁵, Piotr Leszczynski⁶, C Michael Neuwelt⁷, Kathryn Hobbs⁸, Mauro Keiserman⁹, Liliana Duca¹⁰, Kenneth Kalunian¹¹, Sabine Bongardt¹², Christian Stach¹², Carolyn Beaudot¹³, Brian Kilgallen¹³, Catrinel Galateanu¹⁴ and Caroline Gordon^15,16, ¹Rheumatology, Duke University, Durham, NC, ²Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³North Shore LIJ Health System, Manhasset, NY, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Med Pharm Consulting Inc, Cambridge, MA, ⁶Dept. of Rheumatology and Clinical Immunology, J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, ⁷Division of Rheumatology, Alameda County Medical Center, Oakland, CA, ⁸Denver Arthritis Clinic, Denver, CO, ⁹School of Medicine, Pontifical Catholic University, Porto Alegre, Brazil, ¹⁰Clinica Neomed, Brasov, Romania, ¹¹UCSD School of Medicine, La Jolla, CA, ¹²UCB Pharma, Monheim, Germany, ¹³UCB Pharma, Raleigh, NC, ¹⁴UCB Pharma, Brussels, Belgium, ¹⁵Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁶NIHR/Wellcome Trust Clinical Research Facility, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: In phase 2b trials, epratuzumab, a humanized anti-CD22 mAb that modulates B cell signaling without total B cell depletion, significantly improved disease activity in…
Abstract Number: 544 • 2015 ACR/ARHP Annual Meeting
IL-6 May Have an Important Role in the Resistance to Anti-TNF Therapies of Human T-Lymphotropic Virus Type 1 (HTLV-1) Positive Rheumatoid Arthritis (RA) Patients; HTLV-1 Infected Cells Activate the Inflammatory Responses of RA Synovial Fibroblasts
Kunihiko Umekita¹, Shunichi Miyauchi¹, Kazuyoshi Kubo¹, Kazumi Umeki¹, Hajime Nomura¹, Mao Komura¹, Koushou Iwao¹, Ichiro Takajo¹, Yasuhiro Nagatomo¹, Toshihiko Hidaka² and Akihiko Okayama¹, ¹Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan, ²Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan
Background/Purpose: We reported that human T-lymphotropic virus type 1 (HTLV-1) positive patients with rheumatoid arthritis (RA) had higher inflammation and greater resistance to anti-TNF treatment…
Abstract Number: 1205 • 2015 ACR/ARHP Annual Meeting
The Spectrum of Early RA Practice Across the Globe: Results from a Multinational Cross Sectional Survey
Elena Nikiphorou¹, James Galloway^2,3, Piet L van Riel⁴, Andrew Östör⁵, Glenn Haugeberg^6,7, Feride Gogus^8,9, Markku Kauppi¹⁰, Yusuf Yazici¹¹ and Tuulikki Sokka-Isler¹², ¹Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Academic Department of Rheumatology, King´s College London, London, United Kingdom, ³King's College Hospital, Department of Rheumatology, London, London, United Kingdom, ⁴Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, Netherlands, ⁵Addenbrooke's Hospital, Cambridge, United Kingdom, ⁶Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway, ⁷Head of the Department of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁸University of Gazi, Ankara, Turkey, ⁹Gazi University, Faculty of Medicine, Ankara, Turkey, ¹⁰Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ¹¹Rheumatology, Hospital for Joint Diseases and Medicine, NYU Langone Medical Centre, New York, NY, ¹²Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Early diagnosis & treatment are crucial to the management of rheumatoid arthritis (RA). Despite this, the approach to early RA management appears to be…
Abstract Number: 1676 • 2015 ACR/ARHP Annual Meeting
Systematic Review and Network Meta-Analysis of Combination Treatments in Disease Modifying Anti-Rheumatic Drug Experienced Patients with Severe Rheumatoid Arthritis: Analysis of American College of Rheumatology Criteria Scores 20, 50, and 70: An Update
Michelle E. Orme¹, Charles Hawes² and Stephen A. Mitchell³, ¹ICERA consulting UK, Swindon, United Kingdom, ²Pfizer UK, Surrey, United Kingdom, ³Abacus International UK, Bicester, United Kingdom
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (DMARDs) in combination with conventional DMARDs provide patients with severe rheumatoid arthritis (RA) and an inadequate response to conventional DMARDs…
Abstract Number: 2778 • 2015 ACR/ARHP Annual Meeting
Abatacept-Treated Rheumatoid Arthritis Patients Have Better Drug-Survival Rate When Abatacept Is the First or Second Line Biologic Agent with an Excellent Overall Safety Profile: A Single Center Experience
Irini Flouri¹, Argyro Repa², Antonis Fanouriakis², Nikolaos Kougkas², Ioannis Papalopoulos², Eleni Kampouraki², Dimitrios Boumpas³, Nestor Avgoustidis², George Bertsias² and Prodromos Sidiropoulos², ¹Rheumatology, Clinical Immunology, Allergy, University of Crete, Medical School, University Hospital, Heraklion, Greece, ²Rheumatology, Clinical Immunology, and Allergy, University of Crete, Medical School, University Hospital, Heraklion, Greece, ³Biomedical Research Foundation, Academy of Athens, Athens, Greece
Background/Purpose: Long-term prospective observational studies are complementary to controlled clinical trials in exploring the effectiveness and safety of biological therapies in rheumatoid arthritis (RA). We…
Abstract Number: 575 • 2015 ACR/ARHP Annual Meeting
Predictive Factors for Achieving Low Disease Activity at 52 Weeks after Switching from Tumor Necrosis Factor Inhibitors to Abatacept: Results from a Multicenter Observational Cohort Study of Japanese Patients
Toshihisa Kojima¹, Nobunori Takahashi¹, Koji Funahashi¹, Shuji Asai², Toki Takemoto², Nobuyuki Asai³, Tatsuo Watanabe², Naoki Ishiguro⁴ and TBCR Study Group, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: : Currently, there is no clarity regarding which biologic to switch to when patients fail to respond to TNF inhibitors (TNFis). Detailed information for…
Abstract Number: 1222 • 2015 ACR/ARHP Annual Meeting
The Risk of Tuberculosis (TB) in Rheumatoid Arthritis Patients Treated with TNF Inhibitors and the Safety of Resuming Biologic Dmards for Patients Who Developed TB after Anti-TNF Treatment
Soo-Kyung Cho¹, Dam Kim¹, Hye-Jin Jeong², Il Woong Sohn², Soyoung Won³, Minkyung Han³, Jiyoung Lee³, Eun Jin Jang⁴, Sang-Cheol Bae¹ and Yoon-Kyoung Sung¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Information Statistics, Andong National University, Andong-si, South Korea
Background/Purpose: The association between TNF inhibitor (TNFI) treatment and the development of tuberculosis (TB) has been confirmed through several observational studies. Current guidelines strongly recommend…
Abstract Number: 2051 • 2015 ACR/ARHP Annual Meeting
Risk for Lower Intestinal Perforations in RA Patients Treated with Tocilizumab in Comparison to Treatment with TNF Inhibitors, Rituximab, Abatacept or Conventional Synthetic Dmards
Anja Strangfeld¹, Adrian Richter², Peter Herzer³, Karin Rockwitz⁴, Winfried Demary⁵, Martin Aringer⁶, Angela Zink⁷ and Joachim Listing⁸, ¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumatologist, Scientific Advisory Board, München, Germany, ⁴Rheumatologic Practice, Goslar, Germany, ⁵Rheumatologist, Hildesheim, Germany, ⁶Rheumatology, Medicine III, University Clinical Center, Technical University Dresden, Dresden, Germany, ⁷Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁸Epidemiology, DRFZ, Berlin, Germany
Background/Purpose: Interleukin-6 has a direct protective effect on intestinal cells. Although several cases of lower intestinal perforations (LIP) were reported in clinical trials of tocilizumab…
Abstract Number: 2844 • 2015 ACR/ARHP Annual Meeting
Secukinumab Reduces the Burden of Nail and Skin Disease in Patients with Psoriasis and Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies
Alice B. Gottlieb¹, Kristian Reich², Zailong Wang³, Marina Milutinovic⁴ and Shephard Mpofu⁴, ¹Dermatology, Tufts Medical Center, Boston, MA, ²Dermatologikum Hamburg and Georg-August-University Göttingen, Hamburg, Germany, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Nail psoriasis is associated with decreased finger mobility and pain in patients (pts) with moderate to severe plaque psoriasis and psoriatic arthritis (PsA).1,2 Secukinumab,…
Abstract Number: 580 • 2015 ACR/ARHP Annual Meeting
Treatment with Biologic Agents in Rheumatoid Arthritis and Mortality Risk in Clinical Practice
Leticia Leon¹, Luis Rodriguez-Rodriguez¹, Alejandro Gomez-Gomez², Pilar Macarrón², Margarita Blanco², Juan A Jover² and Lydia Abasolo¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: It is a well-known fact the decline of life expectancy in Rheumatoid Arthritis (RA) being the increased mortality in these patients a constant concern…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].